HIF2α inhibitor provides significant clinical benefit in patients with VHL kidney cancer
One of the major breakthroughs this year the hypoxia-inducible factor [...]
Future for VHL kidney cancer is bright
Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always [...]
Cabozantinib plus atezolizumab combination for advanced kidney cancer
In this study, two doses of cabozantinib were tested in [...]
Everolimus and bevacizumab for advanced papillary kidney cancer
In this phase 2 clinical trial, a combination of everolimus [...]
Safety and efficacy of apatinib for metastatic kidney cancer
A recent study coming out of China has identified a [...]
Complete response to immune checkpoint inhibitors in kidney cancer patients
A recent meta-analysis of 6 randomised phase II and III [...]
Comparison of first-line immunotherapy combinations for metastatic kidney cancer
This meta-analysis of first-line immunotherapy trials was published in the [...]
Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors
This retrospective study published in the Journal of Clinical Oncology [...]
ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer
Results from a phase II international trial led by researchers [...]
Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer
Data from a recent phase I study of seleno-L-methionine in [...]
